Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Operations (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Cash from Operations data on record, last reported at 19660000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 176.67% year-over-year to 19660000.0; the TTM value through Dec 2025 reached 24772000.0, up 38.86%, while the annual FY2025 figure was 24772000.0, 38.86% up from the prior year.
  • Cash from Operations reached 19660000.0 in Q4 2025 per TGTX's latest filing, up from 23153000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 83704000.0 in Q3 2023 and bottomed at 86909000.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 28425300.0, with a median of 27178000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: soared 342.66% in 2023, then crashed 249.88% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 86909000.0 in 2021, then skyrocketed by 72.53% to 23870000.0 in 2022, then surged by 44.66% to 13210000.0 in 2023, then crashed by 94.1% to 25641000.0 in 2024, then skyrocketed by 176.67% to 19660000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 19660000.0 in Q4 2025, 23153000.0 in Q3 2025, and 7436000.0 in Q2 2025.